Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206.
Ontology highlight
ABSTRACT: The AKT signaling pathway has been identified as an important target for cancer therapy. Among small-molecule inhibitors of AKT that have shown tremendous potential in inhibiting cancer, MK-2206 is a highly potent, selective and orally active allosteric inhibitor. Promising preclinical anticancer results have led to entry of MK-2206 into Phase I/II clinical trials. Despite such importance, the exact binding mechanism and the molecular interactions of MK-2206 with human AKT are not available. The current study investigated the exact binding mode and the molecular interactions of MK-2206 with human AKT isoforms using molecular docking and (un)binding simulation analyses. The study also involved the docking analyses of the structural analogs of MK-2206 to AKT1 and proposed one as better inhib
SUBMITTER: Rehan M
PROVIDER: S-EPMC4201482 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
ACCESS DATA